September 12, 2011 -- Recent expansion at Melbourn Scientific, a leading provider of analytical and formulation support for the pharma and biotech industries, has created greater capacity for finished product testing prior to release certification. The company has developed its facilities following particular interest from its US clients and will be discussing this service at the AAPS (American Association of Pharmaceutical Scientists) conference in Washington which it is attending for the first time.
CEO Mark Hammond sees a major opportunity for this work.
He says: “We have had interest from US companies in using our analysis and Qualified Person (QP) services to certify batches of medicinal products prior to release for sale within the European Economic Area.
“We were awarded an MIA (IMP) licence earlier this year and this adds significant value to our portfolio of services. As well as our traditional core offerings of analysis and formulation development we can also provide small-scale production and have a QP available to release the product for use in clinical trials. For overseas clients this service can shave valuable time from the development process and enable rapid development of the drug to reach the clinic in a more efficient manner.”
Melbourn Scientific, based in Cambridge UK, has doubled the size of its laboratory space in recent months and has a dedicated team of analysts and formulators, one of the largest teams in Europe. It benefits from a stable workforce so clients placing projects can usually work with the same team as before, which offers considerable consistency in the approach.
Its location, within one of the world’s key clusters of biotechnology and medical device development, means that Melbourn works with companies at the leading edge and it is continually evaluating the latest techniques and instrumentation. At AAPS it will be presenting posters on the application of SprayTech laser diffraction to nebuliser development, the implications of cooled NGI and an evaluation of the Alberta Throat.
For media enquiries: Please contact Rachel Holdsworth/Rebecca Nesbit, 01954 202789, rebecca@holdsworth-associates.co.uk, www.holdsworth-associates.co.uk
Melbourn Scientific: Martin Westcott, Business Development Manager, Melbourn Scientific Ltd, 01763 261648, martin.westcott@melbournscientific.com, www.melbournscientific.com
About Melbourn Scientific
Melbourn Scientific, based near Cambridge UK, provides high quality analytical and formulation services to the pharmaceutical and healthcare industry. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies.
Melbourn Scientific has invested continually in the latest equipment and provides a range of services; formulation and product development; method development and analytical support; stability studies and storage; accelerated feasibility studies, GMP facilities and manufacturing.
